Keraxidil

Keraxidil is an experimental hair-loss compound described as a tyrosinase-cleavable prodrug of minoxidil ^[1][3]. The idea behind it is to keep the drug inactive until it reaches an actively growing hair follicle, where a follicle-associated enzyme releases free minoxidil on the spot ^[3][4]. It is an early-stage agent, and there is little or no independent peer-reviewed research on Keraxidil itself, so most detail about it comes from its developers rather than from the published scientific record.

Minoxidil, the drug at the heart of Keraxidil, has a well-documented history. It was introduced as an oral medicine for high blood pressure, and the observation that it caused excess hair growth as a side effect led to its development as a topical treatment for hair loss ^[1]. Topical minoxidil is now a first-line therapy for androgenetic alopecia, or pattern hair loss, in men and women ^[1][2]. Notably, minoxidil is itself a prodrug: it must be converted by a sulfotransferase enzyme in the follicle to its active form, minoxidil sulfate, and people with higher follicular sulfotransferase activity tend to respond better than those with lower activity ^[1][2].

Keraxidil is intended to exploit a different follicular enzyme, tyrosinase, which drives the production of the pigment melanin and is strongly active in the pigmented bulbs of hair follicles during their growth phase ^[3][4]. Prodrugs that stay dormant until tyrosinase oxidizes them have been studied for years as a way to concentrate drug action in tyrosinase-rich tissues, a strategy developed most extensively for targeting melanoma ^[3][4]. Applied to hair, the same principle is meant to turn the follicle itself into the switch that activates the drug.

By releasing minoxidil chiefly at the follicle, the design aims to preserve the hair-growth benefit while reducing the whole-body vasodilation that accounts for many of minoxidil's side effects, an issue of particular relevance to oral minoxidil, the route reported for Keraxidil ^[1][3]. The precise tyrosinase-sensitive chemistry attributed to the compound is held as proprietary and has not been independently verified.

Because Keraxidil has not been the subject of published clinical or preclinical studies under that name, its efficacy and safety in people are unestablished, and it is not an approved medicine ^[1]. It is best understood as an experimental application of two well-supported ideas, minoxidil pharmacology and enzyme-activated prodrug targeting, whose combination in this specific compound awaits verification ^[1][3].

This is a research compound, listed as laboratory research use only and not for human use, with no human data on the prodrug itself. In principle the whole point is to lower the systemic minoxidil exposure that drives the classic side effects (unwanted body hair, fluid retention, racing heart, low blood pressure), but that is a design goal shown in rodents, not a proven human profile.